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Background: Mutation in SCARB1 gene, exon 8 rs5888, has been associated with altered lipid levels and
cardiovascular risk in humans though the results have been inconsistent. We analysed the impact of SCARB1 single
nucleotide polymorphism (SNP) rs5888 with plasma lipid profile and association with coronary artery disease (CAD)
in a Lithuanian population characterized by high morbidity and mortality from CAD and high prevalence of
hypercholesterolemia.
Methods: The study included 1976 subjects from a random sample (reference group) and an myocardial infarction
(MI) group of 463 patients. Genotyping of SCARB1 (rs5888) was carried out using the real-time polymerase chain
reaction method.
Results/principal findings: Analysis of rs5888 C/T gene polymorphism in the reference group revealed that male
TT genotype carriers (25–74 years) had significantly higher total cholesterol and triglyceride concentrations
(5.70 mmol/l vs. 5.49 mmol/l; p = 0.036, and 1.70 mmol/l vs. 1.40 mmol/l, p = 0.023, respectively) than CT carriers
and the oldest males (65–74 years) TT carriers had significantly higher high density lipoprotein cholesterol
concentrations in comparison to heterozygous (1.52 mmol/l vs. 1.36 mmol/l, p = 0.033). The youngest female
(25–44 years) TT genotype carriers had significantly lower low density lipoprotein cholesterol concentrations in
comparison to C homozygous (2.59 mmol/l vs. 2.92 mmol/l, p = 0.023). The frequency of the SCARB1 TT genotype
in the oldest male MI group (65–74 years) was significantly lower than in the corresponding reference group
subjects (9.4% vs. 22.3%, p = 0.006). SCARB1 TT genotype was associated with decreased odds of MI in males aged
65–75 years (OR = 0.24, 95% CI 0.10-0.56, p = 0.001).
Conclusions/significance: SCARB1 polymorphism is associated with lipid metabolism and CAD in an age- and
gender- dependent manner. Analysis of SCARB1 SNP rs5888 C/T genotypes revealed an atheroprotective phenotype
of lipid profile in older men and in young women TT genotype carriers in the reference group. SCARB1 TT
genotype was associated with decreased odds of MI in aged men.
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Coronary artery disease (CAD) is intimately associated
with dyslipidaemias. Plasma lipid concentration is
influenced by environmental and genetic factors. A
number of variants in candidate genes have been impli-
cated in the regulation of plasma lipid levels [1]. The
scavenger receptor class B type I (SCARB1) is a key
component in the reverse cholesterol transport pathway
where it binds high density lipoprotein cholesterol
(HDL-Chol) with high affinity and is involved in the se-
lective transfer of lipids from HDL-Chol [2,3]. Moreover,
SCARB1 is a multiligand receptor binding other native
lipoproteins such as (i) low density lipoprotein (LDL);
(ii) very low density lipoprotein (VLDL) [4]; and (iii) a
variety of ligands, including modified (acetylated or oxi-
dized) lipoproteins, anionic phospholipids and apoptotic
cells [4,5]. These receptors that were initially found in
cultured macrophages [6], are also highly expressed in
the liver and in steroidogenic tissues [7]; their expression
is regulated by a number of factors including estrogens
[8-13], dietary cholesterol [14] and genetic variation
[13,15]. The importance of SCARB1 in overall choles-
terol metabolism and its antiatherogenic activity in vivo
has been definitively established by SCARB1 gene
manipulation in mice [6]. The role of SCARB1 onTable 1 Fasting serum lipids concentrations of the Lithuanian




25-44 years 45-64 years 65-74 year
N = 168 N = 590 N = 144
TChol, mmol/l CC 5.27 (1.00) 5.52 (1.15) 5.66 (0.98)
CT 5.20 (1.02) 5.58 (1.01) 5.43 (0.98)
TT 5.5 (1.01) 5.76 (1.09) 5.75 (0.99)
Total 5.27 (1.04) 5.59 (0.97) 5.57 (0.96)
LDL-Chol, mmol/l CC 3.32 (0.92) 3.48 (1.00) 3.65 (0.92)
CT 3.37 (0.93) 3.58 (1.01) 3.47 (0.90)
TT 3.56 (0.96) 3.77** (0.99) 3.58 (0.93)
Total 3.38 (0.91) 3.58 (0.97) 3.55 (0.96)
HDL-Chol, mmol/l CC 1.21 (0.38) 1.37 (0.43) 1.42 (0.33)
CT 1.32 (0.37) 1.39 (0.34) 1.36 (0.33)
TT 1.21 (0.43) 1.35 (0.40) 1.52* (0.35)
Total 1.27 (0.39) 1.38 (0.49) 1.42 (0.36)
TG, mmol/l CC 1.68 (0.54) 1.51 (0.86) 1.29 (0.59)
CT 1.40*** (0.56) 1.46 (0.85) 1.32 (0.57)
TT 1.70* (0.58) 1.57 (0.80) 1.43 (0.58)
Total 1.54 (0.52) 1.50 (0.73) 1.33 (0.60)
Data adjusted by age and body mass index (BMI) in each age group. Abbreviations:
Chol – high density lipoprotein cholesterol; TG – triglyceride.
* - means significantly different (p <0.05) between TT and CT.
** - means significantly different (p < 0.05) between TT and CC.
*** - means significantly different (p < 0.05) between CT and CC.cholesterol metabolism in humans was analysed by
studying the influence of SCARB1 gene variants on
plasma lipid concentration [15-23]. Several polymorphic
variants have been described in the human SCARB1
gene [16,19]. Mutation in SCARB1 gene, exon 8 rs5888,
has been associated with altered lipid levels and cardio-
vascular risk in humans [19,21,24], however the results
have been inconsistent [16,18,21-23].
In our study we analyzed the impact of SCARB1 SNP
rs5888 with serum lipid profiles and association with
CAD in a Lithuanian population characterised by high
morbidity and mortality from CAD and a high preva-
lence of hypercholesterolemia [25,26].
Results
Fasting serum lipid concentrations of the Lithuanian
population (reference group) according to SCARB1 ge-
notypes, gender and age are shown in Table 1. For men,
the SCARB1 TT genotype was associated with higher
means of fasting serum lipid concentrations. TT
genotype carriers aged 25–74 years had a significantly
higher total cholesterol concentration than heterozygous
(p = 0.036) and higher than CC subjects (p = 0.050). In
the age group 45–64 years and in all reference groups
(25–74 years) TT genotype carriers had a significantlypopulation (reference group) according to SCARB1
Women
s All 25-44 years 45-64 years 65-74 years All
N = 902 N = 260 N = 652 N = 162 N = 1074
5.49 (1.05) 4.85 (0.89) 5.85 (1.07) 6.02 (1.04) 5.63 (0.98)
5.49 (1.05) 4.89 (0.88) 5.81 (1.08) 6.20 (1.01) 5.65 (1.14)
5.70* (1.12) 4.75 (0.83) 5.96 (1.08) 6.41 (1.08) 5.64 (1.05)
5.53 (0.90) 4.86 (0.81) 5.82 (1.02) 6.19 (1.02) 5.64 (0.98)
3.48 (1.05) 2.92 (0.79) 3.68 (1.07) 3.79 (0.96) 3.51 (0.98)
3.53 (1.05) 2.87 (0.77) 3.67 (1.08) 4.02 (1.01) 3.52 (0.91)
3.68** (1.00) 2.59** (0.77) 3.62 (0.98) 4.22** (0.96) 3.49 (0.92)
3.54 (0.90) 2.84 (0.81) 3.67 (1.02) 3.98 (1.02) 3.51 (0.98)
1.35 (0.35) 1.40 (0.30) 1.51 (0.31) 1.55 (0.30) 1.49 (0.39)
1.38 (0.42) 1.47 (0.33) 1.49 (0.36) 1.48 (0.34) 1.48 (0.45)
1.36 (0.37) 1.50 (0.32) 1.47 (0.39) 1.46 (0.06) 1.48 (0.39)
1.36 (0.30) 1.45 (0.32) 1.49 (0.26) 1.50 (0.38) 1.48 (0.33)
1.50 (0.70) 1.33 (0.49) 1.44 (0.61) 1.50 (0.67) 1.42 (0.59)
1.43 (0.84) 1.36 (0.44) 1.47 (0.72) 1.52 (0.67) 1.45 (0.68)
1.57* (0.75) 1.29 (0.45) 1.50 (0.69) 1.61 (0.66) 1.47 (0.66)
1.48 (0.60) 1.34 (0.48) 1.46 (0.77) 1.54 (0.64) 1.44 (0.66)
TChol – total cholesterol; LDL-Chol – low density lipoprotein cholesterol; HDL-
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3.48 mmol/l, p = 0.022 and 3.68 mmol/l vs. 3.48 mmol/l,
p = 0.035, respectively). Only the oldest (65–74 years)
TT subjects had significantly higher HDL-Chol concen-
trations in comparison to heterozygous (1.52 mmol/l vs.
1.36 mmol/l, p = 0.033). The youngest (25–44 years) TT
genotype carriers had significantly higher serum TG
concentrations than heterozygous (1.70 mmol/l vs. 1.40 -
mmol/l, p = 0.023). The same regularity was observed in
the total reference group (25–74 years) (1.57 mmol/l vs.
1.43 mmol/l, p = 0.037). There were no significant differ-
ences in fasting lipid serum concentrations between CC
and CT genotype carriers with an exception for the TG
concentration in males aged 25–44 years (1.68 mmol/l
and 1.40 mmol/l, p = 0.003).
In women, only the concentration of serum LDL-Chol
was significantly associated with SCARB1 C/T geno-
types. The youngest women (25–44 years) TT genotype
carriers had significantly lower LDL-Chol in comparisonFigure 1 Distribution (%) of SCARB1 C/T (rs5888) genotypes in referen
comparison with a reference group. There are no data on the frequency of
to the small number of study subjects in this group (n = 5).to C homozygous (2.59 mmol/l vs. 2.92 mmol/l,
p = 0.023) and lower than CT subjects (2.59 mmol/l vs.
2.87 mmol/l, p = 0.054). In contrast, the oldest TT geno-
type carriers had significantly higher LDL-Chol than C
homozygous (4.22 mmol/l vs 3.79 mmol/l, p = 0.045).
The frequency of SCARB1 (rs5888) T allele was 36.2%
in the reference group and 40.0% in the MI group. The
frequency of SCARB1 genotypes by gender and age is
presented in Figure 1. There was no significant differ-
ences in SCARB1 C/T genotype distribution between
men and women in both reference and MI groups.
There was a tendency of increased frequency of TT
genotype with age in men and in women from reference
groups. The frequency of TT genotype was lowest in the
25–44 year group and highest in 65–74 year group (in
men - 14.0% vs. 22.3%, p = 0.06, and in women - 16.0%,
vs. 23.1%. p = 0.07, respectively).
The frequency of the SCARB1 TT genotype in the
oldest male MI group (65–74 years) was significantlyce and myocardial infarction (MI) groups. * p = 0.006 in
SCARB1 genotypes in women with MI at the age of 25–44 years due
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jects (9.4% vs. 22.3%, p = 0.006, respectively). Multivari-
able binary logistic regression analysis was performed to
identify the effect of SCARB1 genotype TT vs. SCARB1
genotype CC and CT on the risk of MI; separately for
men and women in all three age groups (25–44, 45–64,
65–74). The results of multivariable logistic regression
analysis showed that SCARB1 TT genotype was associ-
ated with decreased odds of MI only in men aged
65–74 years (OR = 0.24, 95% CI 0.10-0.56, p = 0.001)
compared with the reference group of men aged
65–74 years (data were adjusted by age and BMI).
Discussion
The impact of SCARB1 SNP rs5888 on serum lipid pro-
files and association with CAD in a Lithuanian popula-
tion were studied. According to our data the frequency
of minor T allele in the reference and MI groups wasTable 2 Effect of SCARB1 gene exon 8 SNP rs5888 on serum l
Study subjects Effect of SCARB1 gene exo
White Americans with Coronary artery disease
(n = 371);
No associations with lipid le
Age of 45 yrs and older
White Americans – Amish population (n = 919).
Age of 18 yrs and older.
↑HDL-Chol levels in wome
No associations with lipid c
White Caucasians - population of Geneva,
Switzerland (n = 1756). Aged 35–74 yrs.
↑ HDL-Chol level and HDL
carriers aged 55–74 yrs.
Postmenopausal Caucasian women (n = 689) ↑HDL-Chol among estrog
North Americans/Framingham, USA (n = 2650). ↑HDL-Chol, ↓LDL-Chol.
Aged 26–79 yrs. Associated with an ↑ in H
women.
Healthy white Europeans – Spanish population
(n = 489).
↓LDL-Chol in women.
Mean age: women 36 ± 12 yrs; in men 39 ±
19 yrs.
No associations with lipids
Hypercholesterolemic and normolipidemic
Brasilian individuals (n = 332).
No relation with lipid levels
Aged 29–81 yrs. ↑ response to atorvastatin
Canarian/Spanish population (n = 619). No association with lipid lev
Aged 25 to 79 yrs. ↓Coronary heart disease r
Healthy Spanish men population (n = 59). No difference in fasting lipid
Aged 18–49 yrs. ↓ postprandial TG respon
lipoprotein fraction reflec
Two Chinese populations: Guangxi Bai Ku Yao,
Han (n = 1183).
↓HDL-Chol than in CC or C
Aged 16 to 80 yrs.
Two Chinese populations: Mulao, Han
(n = 1608).
↓HDL-Chol in Mulao fema
Aged 16 to 86 yrs. ↓HDL-Chol in Han males c
↑TG in Han subjects comp
↑ - increases; ↓ - decreases.36.2% and 40.0%, respectively. In Framingham study,
where nearly all subjects were Caucasian, the frequency
of SCARB1 T allele was 48.6% [18]. Whereas in Chinese
population T allele is more recent [27,28]. It’s frequency
was 21.7% in Bai Ku Yao and 26.3% in Han Chinese [27].
The data on the impact of SCARB1 SNP rs5888 on
the serum lipid profile in human populations are incon-
sistent (Table 2). Previous studies reported no influence
on serum lipid profile [15,17,21], while others proved a
beneficial T allele effect on anti-atherogenic lipid profile
[16,18-20,22,23] or even diminished CAD risk [19,21].
The effect of SCARB1 SNP rs5888 depended on age
[19,22] and gender [15,16,19,21]. According to our data
the effect of SCARB1 minor allele T on serum lipid pro-
file depended on gender and age as well. In our study,
male TT genotype carriers had higher LDL-Chol level
than C allele carriers. The difference achieved a signifi-
cant level between T and C homozygous subjects in theipid profile in human populations
n 8 SNP rs5888 (minor T allele carriers) Reference
vels. McCarthy et al.; 2003
[17]
n less than 50 years. Roberts et al.; 2007
[22]
oncentrations in men.
-Chol/LDL-Chol ratio in men CT + TT vs CC Morabia et al.; 2004
[19]
en users. Richard et al.; 2005
[20]
Osgood et al.; 2003
[18]
DL particle diameter in both men and
Acton et al.; 1999 [16]
concentration in men
. Cerda et al.; 2010 [15]
in women.
els. Rodriguez-Esparragon
et al.; 2005 [21]
isk for men.
concentrations by genotype. Tanaka et al.; 2007
[23]
se in the smaller, partially catabolized
ts an antiatherogenic phenotype.
T carriers. Wu et al.; 2012 [27]
les compared with CC or CT carriers; Wu et al.; 2012 [28]
ompared with CC subjects;
ared to CC or CT.
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groups. Beneficial SCARB1 TT genotype effect on HDL-
Chol was found only in the oldest (65–74 years) male
group as opposed to younger men.
An atheroprotective T allele effect on HDL-Chol in
older men was reported by Morabia et al. as well [19].
Contrary to men, a beneficial T allele effect on HDL-
Chol level was reported in women younger than 50 years
[22] or among postmenopausal estrogen users [20]. We
did not find a T allele effect on HDL-Chol level in
women, while a beneficial TT genotype effect on lipid
profile emerged in the youngest female group. Women
TT carriers aged 25–44 years had significantly lower
LDL-Chol levels than C allele carriers. These data are
concordant with the results from the healthy Spanish
subjects investigation [16]. According to our data the TT
genotype effect on LDL-Chol level changed during aging
in women. There was no significant influence of
SCARB1 C/T genotypes on the serum LDL-Chol level in
the female group aged 45–65 years, while in the older
age group we found the same regularity as in men. This
suggests that women TT carriers older than 65 years had
significantly higher LDL-Chol levels than CC genotype
subjects.
Decreased HDL-Chol, raised LDL-Chol and TG levels
are well known risk factors for the development of CAD
and atherosclerosis [29,30]. As discussed above, the
atheroprotective phenotype of lipid profile was found in
older men and in young women TT genotype carriers.
The former had higher HDL-Chol levels while the latter
had lower LDL-Chol levels in comparison to C allele
carriers. Thus our data indicate that the SCARB1 SNP
rs5888 TT genotype has a varying effect on the pheno-
typic lipid profile and that this is dependent on both age
and gender. Moreover, analysis of SCARB1 SNP rs5888
C/T genotypes in a reference group and MI patients re-
vealed a protective effect of the TT genotype in aged
males. We observed the lower frequency of the SCARB1
TT genotype in male MI patients aged 65–74 years as
compared to the corresponding reference group subjects
(9.4% and 22.3% respectively, p = 0.006).
Finally, the men TT carriers aged 65–74 years had sig-
nificantly lower MI risk (OR = 0.24; p = 0.001), while
Rodríguez-Esparragón et al. confirmed that the higher
CAD risk is associated with SCARB1 (C1050T) CC
genotype in males [21]. Atherogenic lipid phenotype had
TT allele carriers in men aged 25–44 years (they have
higher TG level), middle aged men and aged women
(both of the latter have higher LDL-Chol level), but we
did not find an association between TT genotype and
higher risk of MI in these specific age-gender groups.
According to our data SCARB1 rs5888 SNP had influ-
ence not only on the level of HDL-Chol, but on the TG
and LDL-Chol levels as well. SCARB1 was identified asthe first molecularly well defined and physiologically im-
portant HDL receptor [2], but it is also a multiligand re-
ceptor participating not only in HDL-Chol but in other
plasma lipoprotein metabolism. This was demonstrated
by experiments with transgenic mice with liver-specific
overexpression of murine SCARB1. On a chow diet
SCARB1 transgenic mice have decreased HDL-Chol,
apoA-I, and apoA-II levels; serum TG, LDL-Chol, VLDL
and LDL apoB were also decreased, compared with con-
trol mice [31]. Animal studies carried out on rat demon-
strated that immunodetectable SCARB1 is most highly
expressed in the adrenal gland, ovary, and liver and its
expression depends on estrogens [9]. In the same study
it was demonstrated that high-dose estrogen treatment
reduced SCARB1 in the liver and increased SCARB1 in
the adrenal gland and corpus luteal cells of the ovary.
Such estrogen-induced increase in SCARB1 was accom-
panied by enhanced in vivo uptake of lipid from HDL.
Prolonged adrenal stimulation by adrenocorticotropic
hormone in rats and mice decreased hepatic SCARB1
protein expression and it lead to the increase of plasma
HDL-Chol level [32]. The down-regulation by estrogen
effect on SCARB1 was demonstrated in humans as well
[33]. It was shown that females have significantly lower
levels of hepatic SCARB1 expression in comparison to
males. Chiba-Falek O. et al. proposed that the protection
afforded by estrogen in younger women may be limited
to women with a certain SCARB1 genotype [32].
Rodriguez-Esparragon et al. [21] demonstrated that per-
ipheral blood mononuclear cells taken from TT carriers
had higher expression of SCARB1 mRNA in comparison
to C allele carriers. In spite of this, the mechanism of
observed SCARB1 SNP rs5888 influence on lipid profile
remains obscure, as the function of SNP rs5888 is not fi-
nally elucidated. This SNP, despite being in an exon does
not lead to a change in the amino acid sequence and
does not appear to be a functional mutation [16,19].
This SNP might be in linkage disequilibrium with a
functional mutation at a relevant locus [16], or its effect
might be generated through another mechanism such as
some splicing regulatory role [19].
The study has some limitations
Most of patients with MI were receiving lipid lowering
treatment. Thus we were not able to present data on the
impact of SCARB1 SNP rs5888 on lipid profile in these
patients. There are no data on the frequency of SCARB1
genotypes in women with MI at the age of 25–44 years
as well. Data were not analyzed due to the small number
of study subjects in this group (n = 5).
In conclusion, our results suggest that the SCARB1
rs5888 polymorphism is associated with serum lipid pro-
file and MI in an age- and gender-dependent manner.
Analysis of SCARB1 SNP rs5888 C/T genotypes revealed
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men and in young women TT genotype carriers. TT
genotype was associated with decreased odds of MI in
aged men. Further studies are required to explain the
biological basis of the SCARB1 SNP rs5888 effect on
lipid profile.
Materials and methods
Study design and sample
The cross-sectional health survey was carried out in
2006–2008 in Kaunas which is the second largest city in
Lithuania, and in five regions randomly selected from
the northern, southern, eastern, western and central
parts of Lithuania. The random samples of inhabitants
aged 25 to 74 years and stratified by gender, age and
place of residence were randomly selected from the
Lithuanian population register. The eligible initial sam-
ple cohort included 3442 individuals. From these, 2079
(60.4%) underwent a health examination. Individuals
who reported the current use of lipid lowering medica-
tion (N = 90) and women who reported still taking hor-
monal replacement therapy (N = 13) were excluded from
analysis. So, in the study 1976 subjects were presented
as our reference group.
Those who had suffered myocardial infarction (MI) in-
cluded 468 patients aged 28–74 years with an acute MI
or with a history of MI. All MI patients were admitted
to the Cardiology department of the Lithuanian Univer-
sity of Health Sciences with a diagnosis of an acute MI
made on the basis of prolonged chest pain, elevated
troponin I serum levels, ST and T wave abnormalities on
ECG, and typical wall motion abnormalities on the base-
line 2-D echocardiogram; old MIs were diagnosed on
anamnestic and clinical data of the patient and official
medical recordings. From these, only 5 women were
aged 25–44 years, so due to this small number of cases
in this age group they were excluded from analysis. Pa-
tients with MI were receiving lipid lowering treatment.
Finally, this article presents the findings for 2439 sub-
jects: 1976 subjects we presented as a reference group
(902 men and 1074 women) and the MI group included
463 patients (356 men and 107 women).
SCARB1 genotyping
For DNA extraction blood samples were collected in
ethylenediaminetetraacetic (EDTA) tubes at the health
check. DNA was extracted from peripheral blood leuko-
cytes with a kit (NucleoSpin Blood L Kit; Macherey &
Nagel, Düren, Germany) according to the instructions.
Single-nucleotide polymorphism (SNP) of SCARB1
(rs5888) gene was assessed using commercially available
genotyping kit C_7497008_1_ (Applied Biosystems,
Foster City, CA, USA). The Applied Biosystems 7900HT
Real-Time Polymerase Chain Reaction System was usedfor detection of SNP. The cycling program started with
heating at 95°C for 10 min, followed by 40 cycles (at
95°C for 15 s and at 60°C for 1 min). Allelic discri-
mination was done using the software of Applied
Biosystems.
Laboratory analyses and anthropometric measurement
Lipid measurements were done for reference group sub-
jects only. Blood samples were taken in the morning
after fasting at least 12 hours. Total serum cholesterol
(TChol), LDL-Chol, HDL-Chol, and triglyceride (TG)
levels were determined by automatic analyzer by con-
ventional enzymatic methods in a certified laboratory.
The height of participants (without shoes) was mea-
sured with an accuracy of one centimeter, using a
stadiometer. The body weight of participants, wearing
light indoor clothing and no shoes, was measured with
an accuracy of 0.1 kg, using standardized medical scales.
Body mass index (BMI) was calculated as weight divided
by height squared (kg/m2).
Statistical methods
The data were analyzed with the statistical software
package SPSS version 19.0 for Windows. Analyses were
performed separately for men and women. Categorical
variables were expressed as proportion. Continuous
variables were presented as mean values and standard
error (SE).
Statistical analysis using a general linear model (GLM)
was conducted to test the effects of SCARB1 genotype
interaction on TChol, LDL-Chol, HDL-Chol, TG levels.
This model also included age and BMI as continuous
variables. The SCARB1 genotype rates in the male and
female age groups were compared using Fisher’s exact
test. Relationships were considered to be statistically sig-
nificant when p < 0.05.
Multivariable binary logistic regression analysis was
performed to identify the effect of SCARB1 genotype
TT vs. the dual SCARB1 genotypes, CC and CT, with
the risk of an MI in consideration of age, BMI, ex-
pressed as odds ratios (OR) and 95% confidence inter-
vals (CI). Independent variables including age and BMI
were entered into the models as continuous variables.
P values < 0.05 were considered to be statistically sig-
nificant. Multivariable logistic regression analysis was
performed separately for men and women in all three
age groups (25–44, 45–64, 65–74).
Ethics statement
The study protocol was approved by the Lithuanian
Bioethics Committee (Protocol No.BE-2-28; No.05/09).
Written informed consent for the participation in the
study was obtained from all participants.
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